EPS guidance

On its first-quarter earnings conference call, Centene (CNC) guided for 2019 adjusted diluted EPS of $4.24–$4.44, $0.13 higher at the midpoint than its previous guidance of $4.11–$4.31. This expectation is partly attributable to the company’s solid EPS performance in the first quarter, a positive impact of $0.05 per diluted share due to increased estimates for investment income in 2019, and another positive impact of $0.05 per diluted share due to better-than-expected health insurance marketplace revenue. The company, however, expects a negative impact of $0.02 per diluted share associated with rising business expansion costs in 2019.

On its first-quarter earnings conference call, Centene guided for 2019 GAAP (generally accepted accounting principles) diluted EPS of $3.67–$3.84, higher than its earlier guidance of $3.65–$3.83.

Centene Revises Its 2019 EPS Guidance Upward

Ready to put your morning scrolling to use? Sign up for Bagels & Stox, our witty take on the top market and investment news straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.

Analysts expect Centene’s non-GAAP EPS to rise 20.47% YoY (year-over-year) to $4.26 in 2019, 14.49% YoY to $4.88 in 2020, and 14.26% YoY to $5.58 in 2021.

HBR guidance

In its first-quarter earnings press release, Centene reiterated its guidance for a 2019 HBR (health benefits ratio) of 86.5%–87.0%. In the first quarter, the company reported an HBR of 85.7%, a YoY rise of 140 basis points mainly driven by a one-year moratorium on a health insurer fee in 2019 and the company’s acquisition of Fidelis Care. The company, however, reported a 110-basis-point sequential decline in its HBR in the first quarter, which was associated with the performance of the health insurance marketplace business and a one-year health insurer fee moratorium in 2019.

In its first-quarter earnings press release, Centene raised its guidance for its 2019 SG&A (selling, general, and administrative) expense ratio from 9.3%–9.8% to 9.4%–9.9% and reiterated its adjusted SG&A expense ratio guidance of 9.3%–9.8%. The company reported an SG&A expense ratio of 9.5% in the first quarter, a YoY fall of 80 basis points and a sequential fall of 40 basis points.

Latest articles

Last week (ended August 16) was rough for Canopy Growth (WEED)(CGC) stock. It fell about 14% after the company's fiscal 2020 first-quarter earnings report.

Apple shares rose close to 3% in early hour trading on Monday. So, why is Apple stock trading higher? The market sentiment might have turned positive.

In April, Amazon announced its plan to transform its free two-day shipping program to a free one-day shipping program for its Prime customers.

Cannabis companies face regulatory challenges. Recently, CannTrust (CTST) didn't comply with Health Canada’s regulations.

China’s state media agency, Xinhua News Agency, reported on August 18 that police had seized a FedEx parcel containing a handgun.

As of August 17, Curaleaf Holdings (CURA) (CURLF) was trading at 9.00 Canadian dollars—a fall of 13.5% in August.